Pharmacy Daily

Wed 26th Aug 2026



Today's issue of *PD*

Pharmacy Daily today features three pages of news.

PSA wants input

THE Pharmaceutical Society of Australia (PSA) is encouraging pharmacists in all practice areas and settings to contribute to the review of the Dispensing Practice Guidelines.

Feedback will ensure that the guidelines remain up to date and reflect advances in the pharmacy profession.

They were first published by the PSA in 2019 as a foundational resource for pharmacists to support safe dispensing services.

"This review and update is an important opportunity for pharmacists to shape the future of dispensing practice," PSA national president, Professor Mark Naunton, said.

Pharmacists can complete the survey **HERE** by 10 Sep.

PSA welcomes RACGP leader

THE Pharmaceutical of Society of Australia (PSA) has welcomed the appointment of Dr Ramya Raman (**pictured**) as president-elect of the Royal Australian College of General Practitioners (RACGP).

Dr Raman, who previously served as the RACGP's WA faculty chair and the college vice-president, won the election on Mon and will formally assume the presidency at the RACGP AGM in Nov.

She also brings extensive experience as a specialist GP, practice owner and educator.

"On behalf of PSA and the pharmacy profession, I congratulate Dr Ramya Raman on being named RACGP president-elect," PSA national president, Professor Mark Naunton, said.

"Dr Raman has been a passionate advocate for quality primary care and for ensuring Australians can access the healthcare services they need, regardless of where they live.

"The PSA looks forward to continuing its strong relationship



with the RACGP under Dr Raman's leadership, building on shared priorities including workforce sustainability, preventive health, access to care, and the long-term strength of Australia's primary healthcare system."

Professor Naunton also thanked outgoing RACGP president Dr Michael Wright, saying his "support for the integration of pharmacists within general practice settings has helped demonstrate the important role pharmacists can play as part of multidisciplinary care teams". *JM*

Is it the right jab?

PHARMACEUTICAL Defence Limited (PDL) has issued a practice alert urging pharmacists to use extra caution when selecting RSV vaccines, which it emphasised are not interchangeable.

The company highlighted incidents where Arexvy was administered to pregnant women instead of Abrysvo.

As stated in the Australian Immunisation Handbook, "the RSV vaccines Abrysvo and Arexvy are different formulations and are registered for use in a specific age or population group".

Before every RSV vaccine, pharmacists are advised to confirm patient group, eligibility and intended indication.

Other recommendations include physically separating Arexvy and Abrysvo where possible, and discussing RSV vaccine selection during team training and vax refreshers.





Health Services

"More services & support.
Better access.
Stronger community care."



Ruthanne Jaja, TerryWhite Chemmart, Macquarie Street

Pharmacy Daily

Wed 26th Aug 2026



Bowel cancer rise

DOCTORS for Nutrition has launched a new course to help healthcare professionals deepen their understanding of bowel cancer prevention.

The training initiative equips healthcare professionals with practical, evidence-based strategies for protection against bowel cancer, as well as early detection and post-diagnosis support.

Participants can study at their own pace with on-demand access, gaining knowledge across six modules through a series of short lessons, expert presentations, interactive quizzes, and patient handouts.

The course (find it **HERE**) aims to address the alarming surge in bowel cancer among young people, with rates worldwide leaping 266% since the 1980s.

It is also currently the leading cause of cancer death among Australian adults aged between 25 and 54.

AMA warns of AI health scams



THE Australian Medical Association (AMA) has urged the Federal Government to introduce stronger protections against AI deepfakes that are spreading health misinformation.

The technology is being used to impersonate reputable health professionals, exposing patients to potentially unsafe health advice, yet there are no regulations in place to remove the material from digital platforms, the AMA warned in a letter to Prime Minister Anthony Albanese ahead of Scams Awareness Week.

AMA president Dr Danielle McMullen said the false campaigns "can undermine evidence-based care, spread misinformation about prescription medicines, and encourage consumers to abandon clinically validated therapies in favour of unproven alternatives".

"It should not be left to the clinicians whose identities are being stolen and misused to identify, report and pursue the removal of deceptive content.

"The AMA supports a digital duty of care that places responsibility on AI providers and digital platforms to take reasonable steps to prevent foreseeable harms arising from their services," McMullen added.

The association recommended that a regulatory framework be put in place, including mandatory identification of the individual or company responsible for any online post promoting a medical product or service via a publicly accessible and designated contact point.

It also suggested an accessible portal for individuals to report fake, misleading or AI-generated content, time-bound takedown requirements, and appropriate enforcement powers. *JM*

Ultra overhauls

SUNSCREEN brand Ultra Violette has developed a new testing and validation framework, following the failure of its Lean Screen in Choice sunscreen testing in Jun 2025, leading to its subsequent withdrawal from the market.

The brand's mineral sunscreen, which claimed an SPF of 50, was found to have an SPF of 4 (***PD*** 25 Aug 2025).

Ultra Violette has stated that its new standards now "[go] way beyond the standard regulatory requirements".

Prior to launch, every new formula will now undergo at least two, and sometimes up to five, rounds of testing across different independent laboratories, the company said.

The brand has also retested all of its existing products, which consistently returned results above SPF 50.

To read the full update from Ultra Violette, click **HERE**.

Proudly produced by

Raven's recruitment

YOUR PHARMACY CAREER PODCAST

Dive into our latest podcast episode featuring **Iraq Doali**, Sydney community and locum pharmacist, and TikTok creator - "On taking chances, going viral by accident, and building Clutchest Pharmacist".



Proudly brought to you by

Pharmaceutical Society of Australia

Listen on your favourite Podcast app

Pharmacy Daily

Wed 26th Aug 2026



AMH Children's Dosing Companion

ORDER HERE

Dispensary Corner

TRADITIONAL Chinese fitness is the best form of physical activity for people who have musculoskeletal disorders, new research has revealed.


A review published in the *British Journal of Sports Medicine* found that exercises such as tai chi, qigong, baduanjin, wuqinxi and yijinjing were effective in delivering a range of health benefits for people with musculoskeletal conditions.

The Chinese exercises were shown to improve physical function, as well as pain, mental health, sleep quality, and bone mineral density, according to the study, which analysed data from 1,744 randomised controlled clinical trials.

Participants who did these exercises for longer than six months, at least three times a week, derived the most benefit.

"The evidence, particularly for tai chi, reaches high certainty for improving key outcomes such as physical function in knee osteoarthritis, mental health in neck pain, sleep in fibromyalgia and bone density in osteoporosis," the researchers said.

"[These] exercises represent a safe, accessible, and cost-effective strategy that can complement conventional therapies, [and] reduce pharmacological reliance."



PRODUCT SPOTLIGHT

Suppliers wanting to promote products in this feature should email advertising@pharmacydaily.com.au

New product launch: APOHEALTH Celecoxib 200mg 10 capsules

APOHEALTH Celecoxib 200mg 10 capsules for the short-term treatment of acute pain due to primary dysmenorrhea (menstrual cramps), musculoskeletal or soft tissue injuries in adults.

The product is available without a prescription in a 10 pack, after consultation with a pharmacist.



Active Ingredients: Celecoxib 200mg

RRP: A$15.99

Stockist enquiries: Call 1800 276 839 or contact your Arrotex territory manager.

Website: CLICK HERE for more information.

Ask your pharmacist about this product. Incorrect use could be harmful.

Hartley's Gripe Water



Hartley's Gripe Water is a natural blend of herbal ingredients including dill seed oil, peppermint oil, chamomile and coriander oil. These herbs have been used safely in commercial infant preparations for many years.

The product helps reduce the occurrence of excess intestinal wind and gas in infants, and helps relieve the symptoms of infant colic. It does not contain artificial sweeteners.

Suppliers: Available from Symbion, Sigma, API & CH2.

Stockist enquiries: Contact your Clear Sales representative on 1800 640 043 for special deals.

RRP: $11.27 - 200ml bottle

Website: CLICK HERE for more information.

Pharmacy Daily
www.pharmacydaily.com.au

Pharmacy Daily is part of the Business Publishing Group family of publications.

Pharmacy Daily is Australia's favourite pharmacy industry publication.

EDITORIAL
Editor - Karina Bray
Journalists - Adam Bishop, Myles Stedman, Janie Medbury, James Bale
Editor-at-large - Bruce Piper
Associate Publisher - Jo-Anne Hui-Miller
Editorial Director - Damian Francis

ADVERTISING AND MARKETING
Head of Sales & Marketing - Sean Harrigan
Business Development Manager
Kara Stanley
advertising@pharmacydaily.com.au

GENERAL MANAGER & PUBLISHER
Matthew Vince

ACCOUNTS
accounts@traveldaily.com.au

Suite 1, Level 2, 64 Talavera Rd
Macquarie Park NSW 2113 Australia
Tel: 1300 799 220 (+61 2 8007 6760)

info@pharmacydaily.com.au

TRAVELDAILY
CRUISE WEEKLY

Pharmacy Daily is a publication of Pharmacy Daily Pty Ltd ABN 97 124 094 604. All content fully protected by copyright. Please obtain written permission to reproduce any material. While every c are has been taken in the preparation of the newsletter no liability can be accepted for errors or omissions. Information is published in good faith to stimulate independent investigation of the matters canvassed. Responsibility for editorial comment is taken by Damian Francis.